HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Development of novel polymeric micellar drug conjugates and nano-containers with hydrolyzable core structure for doxorubicin delivery.

Abstract
Novel micelle-forming poly(ethylene oxide)-block-poly(epsilon-caprolactone) (PEO-b-PCL) block copolymers bearing doxorubicin (DOX) side groups (PEO-b-P(CL-DOX)) on the PCL block were synthesized. Prepared block copolymers were characterized, assembled to polymeric micellar drug conjugates and assessed for the level of DOX release at pH 7.4 and pH 5.0 using a dialysis membrane to separate released and conjugated drug. The possibility for the degradation of PCL backbone for PEO-b-P(CL-DOX) micelles was investigated using gel permeation chromatography. Micelle-forming DOX conjugate did not show any signs of DOX release at 37 degrees C within 72h of incubation at both pHs, but revealed signs of poly(ester) core degradation at pH 5.0. In further studies, PEO-b-PCL micelles bearing benzyl, carboxyl or DOX groups in the core were also used as micellar nano-containers for the physical encapsulation of DOX, where maximum level of drug-loading and control over the rate of DOX release was achieved by polymeric micelles containing benzyl groups in their core, i.e., PEO-b-poly(alpha-benzylcarboxylate-epsilon-caprolactone) (PEO-b-PBCL) micelles. The in vitro cytotoxicity of chemically conjugated DOX as part of PEO-b-P(CL-DOX) and physically encapsulated DOX in PEO-b-PBCL against B16F10 murine melanoma cells was assessed and compared to that of free DOX. Consistent with the results of in vitro release study, cytotoxicity of micellar PEO-b-P(CL-DOX) conjugate (IC50 of 3.65 microg/mL) was lower than that of free and physically encapsulated DOX in PEO-b-PBCL (IC50 of 0.09 and 3.07 microg/mL, respectively) after 24 h of incubation. After 48 h of incubation, the cytotoxicity of conjugated DOX (IC50 of 0.50 microg/mL) was still lower than the cytotoxicity of free DOX (IC50 of 0.03 microg/mL), but surpassed that of physically encapsulated DOX in PEO-b-PBCL (IC50 of 1.54 microg/mL). The results point to a potential for PEO-b-P(CL-DOX) and PEO-b-PBCL as novel polymeric micellar drug conjugates and nano-containers bearing hydrolyzable cores for DOX delivery.
AuthorsAbdullah Mahmud, Xiao-Bing Xiong, Afsaneh Lavasanifar
JournalEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V (Eur J Pharm Biopharm) Vol. 69 Issue 3 Pg. 923-34 (Aug 2008) ISSN: 0939-6411 [Print] Netherlands
PMID18430550 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibiotics, Antineoplastic
  • Micelles
  • Polyesters
  • Polymers
  • Tetrazolium Salts
  • Thiazoles
  • polyethylene oxide-polycaprolactone copolymer
  • Doxorubicin
  • thiazolyl blue
Topics
  • Animals
  • Antibiotics, Antineoplastic (administration & dosage, pharmacokinetics, pharmacology)
  • Cell Survival (drug effects)
  • Chromatography, Gel
  • Doxorubicin (administration & dosage, pharmacokinetics, pharmacology)
  • Drug Compounding
  • Drug Delivery Systems
  • Electrochemistry
  • Hydrolysis
  • Melanoma, Experimental (drug therapy)
  • Mice
  • Micelles
  • Nanoparticles (chemistry)
  • Particle Size
  • Polyesters (chemistry)
  • Polymers (chemistry)
  • Tetrazolium Salts
  • Thiazoles

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: